This is a Validated Antibody Database (VAD) review about chicken Cek8, based on 12 published articles (read how Labome selects the articles), using Cek8 antibody in all methods. It is aimed to help Labome visitors find the most suited Cek8 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Invitrogen
mouse monoclonal (4C8H5) |
| Invitrogen Cek8 antibody (Invitrogen, 37-1600) was used in western blot on mouse samples at 1:250 (fig 10a). J Neurosci (2022) ncbi |
mouse monoclonal (4C8H5) |
| Invitrogen Cek8 antibody (ThermoFisher, 4C8H5) was used in western blot on human samples (fig 7d). J Virol (2018) ncbi |
mouse monoclonal (4C8H5) |
| In order to show a direct interaction between Sipa1l3 and Epha4 is required for proper eye development, Invitrogen Cek8 antibody (Invitrogen, 37-1600) was used in western blot on mouse samples at 1:1000 (fig 3a). Development (2017) ncbi |
mouse monoclonal (4C8H5) |
| In order to describe the contributions of ephrin-B1 and ephrin-B2 to the migration and proliferation of the intestinal stem cell niche, Invitrogen Cek8 antibody (Life Technologies, 37-1600) was used in immunoprecipitation on human samples (fig 4a) and in western blot on human samples (fig 4a). Exp Cell Res (2016) ncbi |
mouse monoclonal (4C8H5) |
| In order to investigate the role of EphA4 and EphrinA3 in adult axon regeneration using a model of adult mouse optic nerve injury, Invitrogen Cek8 antibody (Invitrogen, 37-1600) was used in western blot on mouse samples at 1:200. Eur J Neurosci (2014) ncbi |
mouse monoclonal (4C8H5) |
| In order to study the increased levels of certain axon guidance proteins in the CNS of Nogo-A ablated mice and their role in limiting the outgrowth of neurites in the absence of Nogo, Invitrogen Cek8 antibody (Invitrogen, 37-1600) was used in western blot on mouse samples at 1:200 (fig 3). Eur J Neurosci (2013) ncbi |
mouse monoclonal (4C8H5) |
| In order to test if EphA4 affects stroke recovery and evaluate Eph44 as a therapeutic target, Invitrogen Cek8 antibody (Zymed, 37-1600) was used in western blot on mouse samples at 1:1000 (fig s2). Hum Mol Genet (2013) ncbi |
mouse monoclonal (4C8H5) |
| In order to investigate the role of Src-like adaptor protein in the context of NMDA receptor signaling, Invitrogen Cek8 antibody (Invitrogen, 37-1600) was used in immunohistochemistry on mouse samples . Mol Cell Biol (2013) ncbi |
mouse monoclonal (4C8H5) |
| In order to elucidate the role of Epha4 in models of amyotrophic lateral sclerosis, Invitrogen Cek8 antibody (Zymed, 37-1600) was used in western blot on mouse samples at 1:1000 (fig 4). Nat Med (2012) ncbi |
mouse monoclonal (4C8H5) |
| In order to test if ADAM family proteins contribute to the development of the neuromuscular junction, Invitrogen Cek8 antibody (Zymed, 4C8H5) was used in immunoprecipitation on mouse samples (fig 5). PLoS ONE (2008) ncbi |
mouse monoclonal (4C8H5) |
| In order to examine neuronal RacGAP alpha2-chimaerin as an effector for the receptor tyrosine kinase EphA4 in cortical and spinal motor circuits, Invitrogen Cek8 antibody (Zymed, 4C8H5) was used in western blot on mouse samples (fig 1). Neuron (2007) ncbi |
BD Biosciences
mouse monoclonal (35/EphA4) |
| BD Biosciences Cek8 antibody (BD Biosciences, 610471) was used in immunohistochemistry - paraffin section on mouse samples at 1:100. Development (2013) ncbi |
Articles Reviewed
- Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats K, Laird A, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18:1418-22 pubmed
- Beg A, Sommer J, Martin J, Scheiffele P. alpha2-Chimaerin is an essential EphA4 effector in the assembly of neuronal locomotor circuits. Neuron. 2007;55:768-78 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments